A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined With Docetaxel in Subjects With Metastatic Hormone-Refractory Prostate Cancer.

Trial Profile

A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined With Docetaxel in Subjects With Metastatic Hormone-Refractory Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Siltuximab (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Centocor
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Apr 2011 Planned end date changed from 1 Feb 2010 to 1 Nov 2009 as reported by ClinicalTrials.gov record.
    • 07 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top